Anxiety/OCD:
Indications for: KLONOPIN
Panic disorder.
Adult Dosage:
≥18yrs: initially 0.25mg twice daily; after 3 days increase to 1mg/day; then may increase every 3 days by 0.125–0.25mg twice daily; max 4mg/day. Orally-disintegrating tabs: dissolve in mouth; swallow with or without water.
Children Dosage:
<18yrs: not established.
KLONOPIN Contraindications:
Significant liver disease. Acute narrow-angle glaucoma.
Boxed Warning:
Risks from concomitant use with opioids. Abuse, misuse, and addiction. Dependence and withdrawal reactions.
KLONOPIN Warnings/Precautions:
Increased risk of drug-related mortality from concomitant use with opioids. Suicidal thoughts or behavior (monitor). Depression. May increase or precipitate tonic-clonic seizures. Compromised respiratory function (eg, COPD, sleep apnea). Porphyria. Monitor LFTs, CBCs during long-term therapy. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Withdraw gradually. Drug or alcohol abusers. Renal impairment. Elderly. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: monitor infants.
See Also:
KLONOPIN Classification:
Benzodiazepine.
KLONOPIN Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiates CNS depression with alcohol, other CNS depressants. Adjust anticonvulsants if needed. Absence seizures with valproate. Caution with drugs that inhibit CYP3A4 (eg, fluconazole). Antagonized by CYP450 inducers (eg, phenytoin, carbamazepine, lamotrigine, phenobarbital); monitor.
Adverse Reactions:
CNS effects (eg, somnolence, depression), confusion, amnesia, liver disorders, GI upset, blood dyscrasias, paradoxical reactions (discontinue gradually if occur); hypersalivation, withdrawal reactions.
Drug Elimination:
Renal. Half-life: 30 to 40 hours.
How Supplied:
Tabs—100; Orally-disintegrating tabs—contact supplier
Seizure disorders:
Indications for: KLONOPIN
Lennox-Gastaut syndrome, akinetic and myoclonic seizures. Absence seizures refractory to succinimides.
Adult Dosage:
Initially up to 0.5mg 3 times daily. Increase if needed every 3 days by 0.5–1mg daily; max 20mg daily. Orally-disintegrating tabs: dissolve in mouth; swallow with or without water.
Children Dosage:
≤10yrs or ≤30kg: initially 0.01–0.03mg/kg per day, but not >0.05mg/kg per day in 2–3 divided doses. Increase if needed every 3 days by 0.25–0.5mg daily. Maintenance: 0.1–0.2mg/kg per day in 3 equally divided doses. Orally-disintegrating tabs: dissolve in mouth; swallow with or without water.
KLONOPIN Contraindications:
Significant liver disease. Acute narrow-angle glaucoma.
Boxed Warning:
Risks from concomitant use with opioids. Abuse, misuse, and addiction. Dependence and withdrawal reactions.
KLONOPIN Warnings/Precautions:
Increased risk of drug-related mortality from concomitant use with opioids. Suicidal thoughts or behavior (monitor). Depression. May increase or precipitate tonic-clonic seizures. Compromised respiratory function (eg, COPD, sleep apnea). Porphyria. Monitor LFTs, CBCs during long-term therapy. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Withdraw gradually. Drug or alcohol abusers. Renal impairment. Elderly. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: monitor infants.
See Also:
KLONOPIN Classification:
Benzodiazepine.
KLONOPIN Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiates CNS depression with alcohol, other CNS depressants. Adjust anticonvulsants if needed. Absence seizures with valproate. Caution with drugs that inhibit CYP3A4 (eg, fluconazole). Antagonized by CYP450 inducers (eg, phenytoin, carbamazepine, lamotrigine, phenobarbital); monitor.
Adverse Reactions:
CNS effects (eg, somnolence, depression), confusion, amnesia, liver disorders, GI upset, blood dyscrasias, paradoxical reactions (discontinue gradually if occur); hypersalivation, withdrawal reactions.
Drug Elimination:
Renal. Half-life: 30 to 40 hours.
How Supplied:
Tabs—100; Orally-disintegrating tabs—contact supplier
